Skip to Main Content

Paper Details

Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.
Neuro Oncol
18
2021
Class I HDAC, HDAC, HDAC2, MAGs, MRGs, MYC, MYC activated genes, MYC amplified cell line, MYC amplified medulloblastoma, MYC protein, MYC repressed genes, class I HDAC, class I HDAC2, class I HDACs, class I histone deacetylase, enhancer-box, entinostat, medulloblastoma, myelocytomatosis oncogene, myelocytomatosis oncogene (MYC) amplified medulloblastoma, tumors
Author NameAffiliation
Venu ThatikondaHopp Children's Cancer Center Heidelberg (KiTZ)
Venu ThatikondaGerman Cancer Research Center and German Consortium for Translational Cancer Research
Nan Qinand Clinical Immunology, University Hospital Dusseldorf
Nan QinGerman Cancer Consortium and German Cancer Research Center
Cornelis M van TilburgHopp Children's Cancer Center Heidelberg (KiTZ)
Cornelis M van TilburgClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center and German Consortium for Translational Cancer Research
Cornelis M van TilburgKiTZ Clinical Trial Unit, Heidelberg University Hospital
Christel Herold-MendeHeidelberg University Hospital
Marc Remkeand Clinical Immunology, University Hospital Dusseldorf
Marc RemkeGerman Cancer Consortium and German Cancer Research Center
Felix SahmHopp Children's Cancer Center Heidelberg (KiTZ)
Felix SahmInstitute of Pathology, University Hospital
Felix SahmHopp Children's Cancer Center Heidelberg (KiTZ)
Felix SahmInstitute of Pathology, University Hospital
Frank WestermannHopp Children's Cancer Center Heidelberg (KiTZ)
Frank WestermannGerman Cancer Research Center
Frank WestermannClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center and German Consortium for Translational Cancer Research
Marcel KoolHopp Children's Cancer Center Heidelberg (KiTZ)
Marcel KoolGerman Cancer Research Center and German Consortium for Translational Cancer Research
Marcel KoolHopp Children's Cancer Center Heidelberg (KiTZ)
Marcel KoolGerman Cancer Research Center and German Consortium for Translational Cancer Research
Robert J Wechsler-ReyaSanford Burnham Prebys Medical Discovery Institute
Robert J Wechsler-ReyaSanford Burnham Prebys Medical Discovery Institute
Lukas ChavezUniversity of California San Diego
Lukas ChavezUniversity of California San Diego
Natalie J??gerGerman Cancer Research Center and German Consortium for Translational Cancer Research
Natalie J??gerGerman Cancer Research Center and German Consortium for Translational Cancer Research
Stefan M PfisterHopp Children's Cancer Center Heidelberg (KiTZ)
Stefan M PfisterGerman Cancer Research Center and German Consortium for Translational Cancer Research
Stefan M PfisterKiTZ Clinical Trial Unit, Heidelberg University Hospital
Stefan M PfisterHopp Children's Cancer Center Heidelberg (KiTZ)
Stefan M PfisterKiTZ Clinical Trial Unit, Heidelberg University Hospital
Stefan M PfisterGerman Cancer Research Center and German Consortium for Translational Cancer Research
Olaf WittHopp Children's Cancer Center Heidelberg (KiTZ)
Olaf WittClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center and German Consortium for Translational Cancer Research
Olaf WittKiTZ Clinical Trial Unit, Heidelberg University Hospital
Olaf WittHopp Children's Cancer Center Heidelberg (KiTZ)
Olaf WittKiTZ Clinical Trial Unit, Heidelberg University Hospital
Olaf WittClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center and German Consortium for Translational Cancer Research
Till MildeHopp Children's Cancer Center Heidelberg (KiTZ)
Till MildeKiTZ Clinical Trial Unit, Heidelberg University Hospital
Till MildeClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center and German Consortium for Translational Cancer Research
  • 1 - 42

Datasets